Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients by race

From: Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital

 

Black

(N = 68)

White

(N = 41)

Hispanic (N = 33)

Other

(N = 7)

P-value

Age at diagnosis (median, [IQR])

58 (51, 66)

58 (52, 65)

53 (44, 59)

61 (43, 66)

p = 0.54

Gender

    

p = 0.30

 Male

6 (8.8%)

9 (22.0%)

5 (15.2%)

1 (14.3%)

 

 Female

62 (91.2%)

32 (78.0%)

27 (81.8%)

6 (85.7%)

 

Insurance

    

p = 0.77

 Private insurance

37 (54.4%)

23 (56.1%)

16 (48.5%)

3 (42.9%)

 

 Medicare

25 (36.8%)

12 (29.2%)

10 (30.3%)

3 (42.9%)

 

 Medicaid

2 (2.9%)

1 (2.4%)

2 (6.1%)

0 (0.0%)

 

 No insurance

4 (5.9%)

5 (12.2%)

5 (15.2%)

1 (14.3%)

 

Income by ZIP codea

    

p < 0.00001

 Quartile 1

25 (36.8%)

2 (4.9%)

10 (30.3%)

3 (42.9%)

 

 Quartile 2

13 (19.1%)

5 (12.2%)

14 (42.4%)

2 (28.6%)

 

 Quartile 3

20 (29.4%)

11 (26.8%)

6 (18.2%)

0 (0.0%)

 

 Quartile 4

10 (14.7%)

23 (56.1%)

3 (9.1)

2 (28.6%)

 

Comorbidities

 HTN

46

22

15

3

p = 0.13

 HLD

18

16

11

2

p = 0.72

 CAD

4

6

2

0

p = 0.38

 Arrythmia

5

2

2

0

p = 0.82

 DM

19

10

9

1

p = 0.87

 Smoking

33

18

10

1

p = 0.18

 FH

20

12

7

2

p = 0.86

 Age > 65

16

11

5

1

p = 0.60

Procedures

 Coronary stents

1

1

0

0

p = 0.81

 Cardiac surgery

0

3

1

0

p = 0.13

Medications pre-chemo

 Beta blocker

11

9

4

1

p = 0.72

 ACEI/ARB

25

13

7

0

p = 0.13

 Diuretic

7

1

2

0

p = 0.41

 Hydralazine

2

0

0

0

p = 0.49

 Nitrate

0

0

2

0

p = 0.37

 MRA

0

0

0

0

p = 1

 CCB

12

3

2

0

p = 0.26

 Antiarrhythmic

0

0

0

0

p = 1

 Aspirin

13

8

2

1

p = 0.35

 Statin

13

10

5

0

p = 0.76

Cancer type

    

p = 0.036

 Breast cancer

57 (83.8%)

24 (58.5%)

24 (72.7%)

5 (71.4%)

 

 Other cancerb

11 (16.2%)

17 (41.5%)

9 (27.3%)

2 (28.6%)

 

Cancer stage

    

p = 0.98

 Stage 1

6 (8.8%)

3 (7.3%)

2 (6.1%)

1 (14.3%)

 

 Stage 2

32 (47.1%)

18 (43.9%)

18 (54.5%)

3 (42.9%)

 

 Stage 3

14 (20.6%)

9 (22.0%)

5 (15.2%)

1 (14.3%)

 

 Stage 4

16 (23.5%)

12 (29.3%)

7 (21.2%)

2 (28.6%)

 

Chemotherapy

    

p = 0.50

 Doxorubicin

24 (35.3%)

22 (53.7%)

15 (45.5%)

3 (42.9%)

 

 Herceptin

39 (57.4%)

15 (36.6%)

14 (42.4%)

4 (57.1%)

 

 Doxorubicin and herceptin

5 (7.4%)

4 (9.8%)

4 (12.1%)

0 (0.0%)

 

Ejection fraction

    

p = 0.75

 Decreasec

19 (27.9%)

11 (26.8%)

6 (18.2%)

2 (28.6%)

 

 No decrease

49 (72.1%)

30 (73.2%)

27 (81.2%)

5 (71.4%)

 

Current status

    

p = 0.60

 In remission

21 (30.1%)

14 (34.1%)

11 (33.3%)

3 (42.9%)

 

 Not in remission

39 (57.4%)

19 (46.3%)

20 (60.6%)

3 (42.9%)

 

 Deceased

8 (11.8%)

7 (17.1%)

1 (3.03%)

1 (14.3%)

 
  1. aZIP codes were used to group patients into quartiles based on median annual household income, with quartile 1 earnings $0 - $18,900, quartile 2 earnings $19,000 – 32,800, quartile 3 earnings 32,900 – 56,000, quartile 4 earnings $57,000 – 130,300
  2. bOther cancer types included lymphoma (Hodgkin’s, T-cell, large cell), multiple myeloma, esophageal cancer, gastric cancer, abdominal desmoid cancer, carcinoid tumor, bladder cancer, ovarian cancer, endometrial cancer, leiomyosarcoma, metastatic cancer with an unknown primary
  3. cDecrease in EF defined by symptomatic reduction in EF by at least 5% to less than 55% or an asymptomatic reduction in EF by at least 10% to less than 55% according to Cardiac Review and Evaluation Committee of Trastuzumab-associated Cardiotoxicity
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us